Kinaset Doses First Patient in Phase 2b Frevecitinib Trial
BOSTON, MA, July 20, 2026 Kinaset Therapeutics announced that the first patient has been dosed in the Phase 2b...
Phase 2b trial
Advertisement
Can-Fite Secures Australian Patent for Namodenoson in Liver and Pancreatic Cancer
Ramat Gan, Israel, July 14, 2026 Can-Fite BioPharma announced that the Australian Patent Office has allowed Patent Application No....
Vaxart Reports Positive 12-Month Phase 2b Safety Data
SOUTH SAN FRANCISCO, Calif., July 6, 2026 Vaxart, Inc. has announced positive topline 12-month safety results from the approximately...
Bial Discontinues Pariceract After Phase 2b ACTIVATE Trial Miss
PORTO, Portugal, June 9, 2026 Bial announced topline results from its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract)...
Structure Therapeutics Highlights Aleniglipron Phase 2b Success
SAN FRANCISCO, June 5, 2026 Structure Therapeutics Inc. announced the publication of detailed results from its Phase 2b ACCESS...
Advertisements
Ascletis Showcases Next-Generation Obesity Pipeline at ADA 2026
HONG KONG and NEW ORLEANS, Louisiana, June 8, 2026 Ascletis Pharma has strengthened its position in the highly competitive...
Berobenatide Shows Strong Weight Loss With Monthly Dosing
NEW ORLEANS, Louisiana, June 6, 2026 New data presented at the American Diabetes Association (ADA) 2026 Scientific Sessions have...
OS Therapies Advances OST-HER2 Ahead of ASCO 2026 Presentation
NEW YORK and ROCKVILLE, Md., May 29, 2026 OS Therapies announced the publication of four scientific articles focused on...
Biogen, Denali End BIIB122 Parkinson’s Program
CAMBRIDGE, Massachusetts and SOUTH SAN FRANCISCO, California, May 21, 2026 Biogen Inc. and Denali Therapeutics Inc. announced that the...
TaiMed Advances Long-Acting HIV Therapy Into Late-Stage Development
TAIPEI, Taiwan, 21 May 2026 TaiMed Biologics announced the completion of enrollment in its Phase 2b clinical study evaluating...
Advertisement
